AIDS turned 20 years old on 5 June 2001; it has to date claimed the lives of 21 million individuals, mostly within Africa. 1 During the last 20 years, there has been remarkable progress in the therapy of HIV disease. At the beginning, all that was offered was prophylaxis and treatment of the opportunistic infections that are the hallmark of immunodeficiency. The first drug that was active against HIV, zidovudine (AZT), was licensed in 1987 in the US. Since then, advances have not only involved the development of new drugs, but also the use of these drugs in appropriate combinations. The use of so-called highly active antiretroviral therapy (HAART) since 1995 has led to a remarkable improvement in the prognosis of HIV disease: 2 there has been a decrease in AIDSrelated deaths, reduction in the use of drugs for opportunistic infections, and a decrease in the numbers of patients hospitalised with AIDS-related illnesses. HIV can now be classified as a chronic disease; until a cure is found, patients are likely to require life-long therapy. However, despite these undoubted advances, there are many issues that need to be resolved, including the problems associated with long-term efficacy and toxicity.
Pharmacogenomics has been widely hailed as a means to improve prescribing for all drugs. 3 However, pharmacogenomics is likely to be particularly useful for drugs that have variable kinetics and dynamics, and a narrow therapeutic index. Anti-HIV drugs certainly fit this category. Although there are many issues that need to be handled in the next 20 years in the fight against HIV, 1 individualisation of therapy through the use of pharmacogenomics has the potential to resolve some of the problems with currently available anti-HIV drugs as well as with the new drugs being developed. An additional area that needs to be considered in relation to HIV therapy is the genetic diversity of the virus itself. The purpose of this review is to highlight potential areas where pharmacogenomics may be of use in both maximising the efficacy and minimising the toxicity of antiretrovirals, in particular to:
¼ improve the failure rate of current drug regimes; ¼ overcome the problems associated with kinetic variability of antiretrovirals; and ¼ reduce the short-and long-term toxicities of the drugs.
CURRENT PRACTICE AND PROBLEMS OF ANTI-HIV THERAPY
The currently licensed antiretrovirals fall into three classes, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) 4 (Table 1) . With the available drugs, eradication of HIV is not likely to be possible. The aim of treatment is therefore to prolong life and improve the quality of life by maintaining suppression of viral replication for as long as possible. 5 There is controversy as to the stage of disease drug therapy should be commenced and differences may exist in treatment guidelines. The three groups of treatment naive patients for whom treatment guidelines are required are:
¼ patients with primary HIV infection, ¼ patients with asymptomatic HIV infection and ¼ patients with symptomatic HIV disease or AIDS.
The recommendations of the British HIV Association (BHIVA; http://www. bhiva.org) are summarised in Table 2 .
The putative benefits of treatment during primary HIV infection (PHI) have to be weighed against the known risks of toxicity. Furthermore, despite suppression of viral load, HIV replication may continue with an associated risk of development of drug resistance or transmission of drug resistant virus. 6 It has to be assumed that lifelong treatment will be required even when initiated in PHI. All patients with late disease and/or symptomatic HIV with a CD4 count below 200 cells l Ϫ1 or who have been diagnosed with AIDS or severe/recurrent HIV related illness should start therapy. The debate of when to start treatment tends to centre on patients with established HIV infection but who are asymptomatic. Ultimately the decision must be to ensure that the benefits of currently available therapies outweigh the risks of deferring therapy.
Evidence is overwhelming that patients should commence therapy with a HAART regimen. 2, 7, 8 Any HAART regimen should be individualised in order to achieve the best potency, adherence and tolerability, to minimise toxicity and avoid problems of drug-drug interactions. The aim must be to achieve a viral load Ͻ50 HIV-RNA copies ml Ϫ1 at 6-9 months. The choice of initial therapy is: the primary reason for combining PIs is to improve pharmacokinetics. There is wide use of ritonavir as a pharmacoenhancer). ¼ 3NRTIs.
Despite the undoubted short-term efficacy of these combinations, it has ) by 48 weeks. 9 Even if there is initial success, many patients eventually have to change their initial drug regime either because of viral rebound or toxicity. For example, in the Swiss cohort study, rebound HIV viraemia was approximately 10% per year in treatment-naive patients commencing therapy, and 20% per year in treatment-experienced patients switching therapy. 6 In another cohort, viral rebound was observed in 50% of patients within 12 months of achieving undetectable viral RNA. 10 Toxicity is observed in many patients on
The Pharmacogenomics Journal HAART; although many of these adverse effects are minor and dependent on dose, they nevertheless affect the tolerability of HAART, and hence adherence to it. 11 Recently, and perhaps more worrying in respect of the long-term effects of HAART, have been reports of lipodystrophy, a fat redistribution syndrome associated with metabolic abnormalities that may have consequences for the development of atherosclerosis in this patient cohort. 12 The levels of the drugs within the blood and tissues, how they are handled by the body, and the effect they have on host biological processes (as opposed to the virus) are all subject to variation between individuals, and form the basis for either failure or toxicity of the different drug regimes.
GENOMICS OF VIRAL RESISTANCE
The goal of antiretroviral therapy is to completely suppress viral replication. If left untreated, HIV replicates at a rapid rate. 13 Taken together with the fact that HIV has a high propensity to mutate, it is likely that each new virus particle will contain at least one mutation. 13 During the process of transcription of the proviral DNA from the viral RNA, reverse transcriptase makes errors relatively frequently. The errors can be of two main types: substitutions, where one nucleotide replaces another and insertions/deletions of one or more nucleoside in the proviral DNA chain. Given the high level of viral replication and turnover (typically around 10 9 viral particles per day 14 ), this creates the potential for large numbers of genetically distinct quasi species to be created. Some mutations result in small changes in the structure of proteins such as reverse transcriptase and/or protease. If these changes are at the site of action of antiretroviral drugs, then it is possible that one or more drugs will not bind correctly to the target protein. Ongoing viral replication will occur in the presence of drug and a resistant quasi species will become the dominant form of the virus in the patient. The clinical implication of this is that once resistance develops, the treatment will fail and disease may progress. 15 Some of the key mutations associated with the development of resistance are shown in Table 3 .
The importance of viral resistance in reducing success rates is evidenced by the fact that patients who are treatment-experienced have lower success rates on second-line and salvage therapies. 16 Genotypic assays that detect mutations have been shown to predict response to antiretrovirals. [17] [18] [19] [20] [21] For example, among patients who experienced HAART failure, viral suppression (Ͻ500 copies ml Ϫ1 ) at 12 weeks was more common among patients for whom genotypic anti-retroviral resistance testing and clinical judgment 
The mutations indicated in bold are the key mutations associated with resistance to the individual drugs.
were used to guide the choice of a second-line or subsequent regimen (34%) than among those whose treatment was determined by clinical judgment alone (22%). 21 Furthermore, cost-effectiveness analysis using models derived from patient data has shown that genotypic testing for secondary resistance increases life expectancy by 3 months, at a cost of $17 900 per quality-adjusted life year gained. 22 Primary resistance testing was less cost-effective, although this was dependent on the prevalence of resistance in primary isolates, the cost-effectiveness increasing as the background resistance rate increased. Based on efficacy and cost-effectiveness data, resistance testing is now recommended in several guidelines. 5, 23 Indeed, its effectiveness is likely to be enhanced by concomitant therapeutic drug monitoring. 17 Clearly these guidelines have been developed for use in the US and Western Europe. It is important to note in these countries, the B subtype of HIV-1 accounts for the vast majority of infections. 24 By contrast, in the northern part of sub-Saharan Africa, the A subtype predominates, while in southern African, the C subtype is most prevalent. The entire genomes of A, B www.nature.com/tpj and C HIV-1 subtypes show variations in the order of 10-30%. 24 Interestingly, these variations are most pronounced in matrix proteins, which can show up to 27% variation, and least pronounced in essential enzymes such as reverse transcriptase, which shows 7-9% variation. A recent study has shown that the protease from the A subtype, which differed from the consensus B subtype sequence in seven amino acid positions, had 1.5-5 times higher vitality than the B subtype. 24 Similarly, the C subtype, which differed in four amino acid positions, had 4-11 times higher vitality than the B subtype. 24 Thus, although the current practice of resistance testing has been shown to be clinically and cost-effective in the Western world, whether this holds true in Africa, where HIV is exerting the greatest burden, is unclear. Nevertheless, determination of variation in essential viral enzymes such as the protease, may allow the development of newer agents with a greater ability to inhibit the proteases from the different subtypes, and thereby improve long-term outcome.
Although viral resistance testing is now recommended in guidelines, there are several issues that need to be studied further. 25 First, genotyping will only detect the predominant viral populations in circulation, with those representing less than 10-50% of the viral population being missed. The importance of these minor subtypes on long-term prognosis needs further study. Second, the results of genotypic testing need careful and expert interpretation, which may not be available in all centres. Furthermore, in vitro testing does not take into account the synergy between the different drugs used in combination. Phenotypic tests although easier to interpret and equivalent to genotypic testing 26 are more expensive than genotypic tests. Finally, although resistance testing is indicated in patients who have failed on one or more treatment regimes, its value in the detection of primary resistance, ie before drug therapy has begun, is unclear.
INTERINDIVIDUAL VARIABILITY IN RESPONSE TO ANTIRETROVIRALS: IMPACT OF GENOTYPE ON PHARMACOKINETICS
Among HIV-infected patients there is considerable variability in the response to antiretroviral therapy and one critical factor is the marked inter-patient difference in plasma concentrations arising from the same drug regimen. 4 Although this is seen with all three classes of drugs (NRTIs, NNRTIs PIs), most attention has been focused on PIs and NNRTIs for two reasons. Firstly, NRTIs have to be phosphorylated by cellular kinases to the active triphosphate anabolite, so that plasma concentrations of the parent nucleoside do not reflect the concentration of the intracellular active drug. 27 Secondly, both PIs and NNRTIs are substrates for cytochrome P450 (CYP450) isoforms 28 and transporter molecules such as P-glycoprotein and multi-drug resistance protein. 29, 30 There is currently much interest in the role of genetic polymorphisms in enzymes and transporters in determining pharmacokinetic variability and in seeking to elaborate how such information may be brought to impact on HIV patient management.
Metabolic Enzymes
Several polymorphisms that affect genes encoding CYP450 enzymes have been described (Table 4-see Ingelman-Sundberg   31 ). In clinical pharmacology, polymorphisms in the gene encoding CYP2D6 have attracted much attention. 32 This P450 is responsible for the metabolism of more than 100 drugs including many CNS and CVS drugs. 33 The Pharmacogenomics Journal CYP2D6 activity can give rise to drug accumulation due to reduced clearance. 34 However, most of the drugs metabolised by CYP2D6 have a wide therapeutic index and are amenable to dose reductions. Allelic variants of CYP2C9 and CYP2C19 lead to inactive enzyme or enzyme with reduced affinity for substrate. 35 This can impact on dose requirements.
Absent or reduced
Of the human CYP proteins, members of the CYP3A subfamily are of major importance since they form the largest portion of the liver (and enterocyte) CYP protein. 33 Although CYP3A4 is most often discussed, the human CYP3A subfamily actually consists of three homologous proteins (CYP3A4, CYP3A5, CYP3A7) encoded by distinct genes. 36 ,37 CYP3A4, the major isoform in the CYP3A family, shows extensive (Ͼ30-fold in some studies) variation in expression. Several allelic variants, which may be functionally active, have been described. 31 Additionally, more recently, the molecular basis of the polymorphic expression of CYP3A5 has been described. 38 CYP3A5 is expressed in 70% of individuals, and when present may account for about half of the variability in CYP3A activity. CYP3A7 was originally isolated from fetal liver but has subsequently been shown to be present in Ͼ50% of adult livers.
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CYP3A activity exhibits considerable interindividual variability and this is assumed to reflect the combined effect of modulation by environmental factors and to a large extent so far unidentified genetic factors. Recently, polymorphisms affecting amino acid sequence have been found in CYP3A4 (Table 4 ) and the contribution of these alleles to the variability of CYP3A4 expression or activity is currently being determined. 31 Another important aspect is the increased expression of CYP3A genes by a range of drugs. The induction of CYP3A is the result of transcriptional activation. Recently a number of studies have led to the identification of a human orphan nuclear receptor, the pregnane X receptor (hPXR) as a major activator of CYP3A transcription. [39] [40] [41] Whether the variability in induction can be explained by the recently described polymorphisms in the PXR gene 42 needs further study.
Possible ethnicity differences in CYP3A activity have been explored. The probe drug midazolam was simultaneously administered intravenously and orally to young healthy European American men and a similar group of men of African American descent. Subjects were genotyped with respect to CYP3A4*B1. With one exception, the African Americans possesed a variant CYP3A4*B1 allele (four heterozygotes A/G and 10 homozygotes G/G), whereas all European Americans were homozygous wild type (A/A). Hepatic CYP3A activity and systemic clearance of midazolam was about 30% lower in G/G compared to A/A homozygotes. 43 This modest difference needs to be confirmed in other studies and clearly there is a requirement for studies involving antiretrovirals in such populations.
Although polymorphisms in the P450 genes have attracted most attention, it is important to note that phase II enzymes are also involved in the metabolism of antiretrovirals. Thus, polymorphisms in genes coding for phase II enzymes such as glucuronyl transferase, 44 may also be important.
P-glycoprotein (P-gp)
P-glycoprotein (P-gp), the product of the multidrug transporter MDR1 gene, plays a major role in transport of many different substrates including some antiretroviral drugs at compartmental and cellular levels. 29, 30, [45] [46] [47] At the intestine, P-gp limits drug entry into the body. P-gp is also present in the apical membrane of many other epithelial barriers such as the bloodbrain, blood-testis, and maternal-fetal barrier. In addition, P-gp is expressed in haematopoietic progenitor cells, macrophages and lymphocytes. 47 Thus P-gp limits drug penetration into pharmacological sanctuaries and HIV cellular targets. In these areas, virus may persist and replicate, despite apparent suppression of replication in plasma. Multidrug transporters such as P-gp and multidrug resistance associated protein (MRP) could play an important role in lowering therapeutic drug concentrations at these sites via an efflux mechanism. In vitro, overexpression of P-gp diminishes the intracellular concentration of protease inhibitors. 29 Therefore differences in P-gp (and MRP) expression could lead to marked differences in accumulation of antiretrovirals in various compartments. 48, 49 Because of its association with drug resistance to cytotoxic agents and influence on therapy outcome (leukaemia with high P-gp levels has a poor prognosis 50 ), considerable efforts www.nature.com/tpj have been made to develop compounds that modulate P-gp activity. Examples of so-called first generation P-gp blockers are verapamil and quinidine. Second generation compounds include PSC833, GF120918 and XR9576.
One important question is whether allelic variants of MDR1 account for some of the interindividual variability in the pharmacokinetics (and consequently efficacy) of antiretrovirals. Mickley et al 51 reported the first evidence of the presence of polymorphisms in the human MDR1 gene. A screen of the entire MDR1 gene for the presence of SNPs was undertaken by Hoffmeyer et al. 52 SNPs that change amino acids and thus possibly have an affect on protein function are located at position A61G in exon 2 and at position G1199A in exon 11. However, no correlation between these SNPs and altered function or activity of P-gp has been reported. However, a C 3435 T change at a wobble position in exon 26 has been shown to have pharmacological consequences. 52 The MDR1 genotype at the SNP position correlates with P-gp expression in the intestine, patients homozygous for the T-allele having low expression of P-gp. The C 3435 T SNP has also been shown to be correlated with Pgp expression and function on lymphocytes, 53 but not in placenta. 54 It is possible that its effects may be tissue-specific, since the C 3435 T polymorphism is a noncoding, non-promoter SNP, and may be linked to an SNP that affects gene expression in regulatory regions of the MDR1 gene. 49 Individuals carrying the homozygous low-expressor (T) allele (25% of the Caucasian population 55 ) show increased digoxin plasma levels due to increased uptake. 52 However, in contrast, in a study of HIV patients, low Pgp expression linked to the MDR1 3435 TT genotype was associated with low plasma levels of nelfinavir and efavirenz. 56 Patients with MDR1 3435 TT genotype presented median nelfinavir levels at percentile 30, compared to patients with CT genotype at percentile 50 and CC genotype percentile 75 (Fellay et al, personal communication) .
Quantification of MDR1 transcripts in
PBMCs demonstrated an association between MDR1 3435 TT genotype and lower MDR1 expression level. The fact that nelfinavir plasma levels are low in the presence of low P-gp suggests that there is an indirect effect of the MDR1 3435 genotype and the actual mechanism awaits clarification. For example, there may be overexpression of another transporter or upregulation of a CYP enzyme.
The frequency of the C 3435 T mutation is significantly influenced by ethnicity, 55 ,57,58 marked differences in genotype and allele frequency being seen between African populations and Caucasian/Asian populations. A high frequency of the C allele in African subjects implies overexpression of Pgp, and could have considerable implications for use of P-gp dependent drugs (such as antiretrovirals) in individuals of African origin.
The Liverpool HIV Group have recently determined drug efflux transporter (P-gp and MRP) expression on PBMCs and the concentration of saquinavir and ritonavir within cells in HIV patients receiving HAART. Patients with lower MRP1 expression had a significantly higher intracellular concentration of both ritonavir and saquinavir than patients with higher MRP1 expression. Ritonavir accumulation was also significantly greater in patients with lower P-gp expression. 59 Clearly, genetic variability and functional polymorphisms in ABC transporters are relevant pharmacological factors that have to be considered together with drug-metabolising enzymes in order to understand variability in drug response. Understanding these genetic parameters could be the starting point for individualised drug therapy.
DISEASE PROGRESSION AND RESPONSE TO ANTIRETROVIRAL THERAPY
The progression of HIV infection, as well as susceptibility to HIV infection, varies widely among individuals. Studies in long-term nonprogressors and exposed but uninfected individuals have shown that genetic factors play an important role in determining the course of HIV infection. For example, homozygosity for the CCR5-⌬32 deletion is associated with decreased susceptibility to infection, while heterozygosity is associated with delayed progression to disease. [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] Recent studies have also shown that chemokine receptor gene polymorphisms may affect response to HAART. [73] [74] [75] However, these effects were quite modest, and larger prospective studies are required to confirm these initial findings, and to determine whether they are related to individual drugs or certain combinations. Relationships between polymorphisms in HLA, cytokine, and chemokine genes and disease progression have also been identified 76 but whether they also determine response to HAART has not been studied.
The relationship between genes determining disease progression and drug response requires much further study, and is likely to be increasingly important in the future. For example, the finding that HIV requires co-receptors such as chemokine receptors for entry into cells 77 has led to the development of drugs that will antagonise these receptors or prevent their expression. 76 Their use and effectiveness will probably be increased by prior knowledge of the chemokine receptor genotype. It is also possible that drug therapy may need to be individualised on the basis of progressor status, with those individuals classified as being slow progressors receiving less potent therapy in order to avoid some of the toxic manifestations of the antiretrovirals. In order to reduce the emergence of resistant strains and prevent or minimise adverse effects of antiretrovirals, studies are being performed to examine the utility of structured treatment interruptions. 76 Preliminary results have suggested that structured treatment interruptions may lead to immunologic control of viraemia in the absence of antiretroviral therapy. [78] [79] [80] Whether these effects show inter-individual variability and can be related to genetic determinants is unknown, but opens up the intriguing possibility that treatment interruptions could be individualised according to genotype. 
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TOXICITY OF ANTIRETROVIRALS
Adverse effects associated with antiretrovirals are common, and can be divided into several different categories ( Table 5 ). The whole area of adverse effects in HIV disease has been reviewed recently. 81, 82 This is an increasingly important area given that the drugs, which have a narrow therapeutic index, have to be used for long periods, and are used in combinations that are liable to result in interactions.
Adverse effects to drugs are generally divided into dose-dependent and dose-independent reactions. 83 Although this is an over-simplification, since there is a dose-response relationship for most, if not all, adverse reactions, it serves as a useful classification to discuss the role of genetic susceptibility. Genetic factors probably play a role in predisposing to all adverse reactions (although the degree will vary), 34 and one of the major goals of pharmacogenomics in the future will be to prevent adverse reactions by developing SNP profiles that are predictive of individual predisposition. 84 Indeed, this has been set as a goal by GlaxoSmithKline in order to prevent hypersensitivity reactions to abacavir. 85 Nevertheless, we are a long way from achieving this goal, and very little research has so far been carried out with toxicities associated with antiretrovirals.
As stated above, there are marked inter-patient differences in plasma concentrations arising from the same drug regimen. 4 For those adverse reactions where a clear dose-response relationship can be demonstrated, it can be hypothesised that patients who have low expression or deficiency of a particular metabolising enzyme will achieve high plasma drug concentrations and hence toxicity. Although this has clearly been shown with non-HIV drugs metabolised by polymorphic enzymes such as CYP2D6, 34 to date no such studies have been performed in HIV disease. With respect to antiretrovirals, the CYP3A family may be a fruitful area for research, since a number of drugs metabolised by this enzyme, 28, 86 commonly cause adverse effects that have been shown to be dose-dependent. For example, with indinavir, drug crystallisation in urine and the formation of renal stones is a known adverse effect associated with high indinavir plasma concentrations. 87 Although environmental factors such as hot climate are also important, 82 the role of CYP3A4 and CYP3A5 polymorphisms needs to be investigated, and may allow individualisation of therapy at initiation so that plasma levels are optimised to suppress viral replication, while at the same time avoiding urinary crystallisation. A good relationship has also been shown between ritonavir and neurological and gastro-intestinal adverse effects. 88 Clearly for both indinavir and ritonavir, 30 the MDR1 polymorphism may also be important in determining plasma levels. A similar situation also exists with the NNRTI efavirenz, where high plasma levels predict CNS side effects such as dizziness, hallucinations, nightmares, and psychiatric symptoms, while low levels predict virological failure. 89 It is however more difficult to show the same dose response relationship between NRTIs and adverse effects, since these drugs need to undergo conversion intracellularly to their triphosphate anabolites. 27 The genetic basis of the mitochondrial toxicities associated with the NRTIs is unclear. Given the similarity of these toxicities with rare mitochondrial disorders, 12 the mitochondrial genome is an obvious area of study. However, any genetic predisposition also needs to explain the tissue specificity of some of the adverse effects reported with the different drugs. Thus, genes not encoded by the mitochondrial genome also need to be investigated. For example, adefovir is associated with proximal renal tubular toxicity, and this is thought to be due to its selective accumulation within the proximal tubular cells by the influx transporter OATP-1. 90, 91 Transport of the NRTIs into the mitochondria is also likely to vary in a drug-and individual-specific manner and may be dependent on variation in the human mitochondrial deoxynucleotide carrier. 92 Hypersensitivity reactions in HIVpositive patients are seen with all three www.nature.com/tpj classes of antiretroviral drugs. 93 The frequency of such reactions is relatively high in comparison to the frequency seen in HIV-negative individuals with other drugs. Very little is known about the mechanisms of these reactions, and indeed, their classification as hypersensitivity reactions implying that they are immunemediated, is based on the symptomatology rather than specific laboratory evidence of an immune pathogenesis. No genetic studies have so far been performed with the antiretrovirals associated with hypersensitivity, although plans are underway to carry out whole genome screening in patients with and without abacavir hypersensitivity. 85 Taking hypersensitivity reactions in non-HIV patients as an illustration, it is likely that the genetic predisposition is going to be polygenic, 93 and genes involved in determining immune responsiveness will play a more important role than those involved in determining drug disposition. For example, hypersensitivity to carbamazepine, an anticonvulsant, has recently been shown to be associated with a promoter region polymorphism in the TNF-␣ gene and HLA DR3, 94 while the genes coding for enzymes responsible for metabolism of carbamazepine did not show an association with hypersensitivity.
95
Lipodystrophy
The syndrome of lipodystrophy or fat re-distribution syndrome was first reported about 3 years ago. [96] [97] [98] [99] [100] This syndrome has caused a great deal of concern, and is currently the subject of intense research. It is characterised by morphological abnormalities including peripheral fat loss (in face, limbs and buttocks) and fat accumulation (in the abdomen, breast and dorsocervical spine). The syndrome is also associated with metabolic abnormalities such as dyslipidaemia and insulin resistance, which in some cases is manifested as frank diabetes mellitus. In the long term, there are worries that the syndrome may be associated with the development of ischaemic heart disease, cerebrovascular disease and osteopenia.
The syndrome was initially reported with PIs, but it is now known to occur with NRTIs as well, 12 and indeed is probably the result of a complex (as yet undetermined pathogenesis) interaction between the disease, PIs and NRTIs, as well as host genetics. In HIV-negative patients, many of the lipodystrophies are thought to be inherited, although these are much less common than the LD observed in HIV-positive subjects. 101 The situation in HIV patients is complicated by the fact that: (a) lipodystrophy is not a single disease entity and is probably a collection of overlapping syndromes; and (b) there is no good case definition. 102 Thus, dissection of genetic predisposition is going to be difficult. Nevertheless, using a case-control design, we have been able to show an association between the Ϫ238 promoter region TNF-␣ gene polymorphism (G→A), but not the Ϫ308 polymorphism, and lipodystrophy. 103 The TNF-␣ gene was chosen as a candidate gene because it is thought to play a role in insulin resistance, 104 adipose tissue metabolism 105 and viability 106 and glucose homeostasis. 107 Furthermore, this polymorphism is thought to be functionally active, 108 although whether TNF-␣ secretion is increased or decreased in adipose cells as a result of the G→A substitution is not known. This should be regarded as the first step in the genetic dissection of lipodystrophy in HIV-positive patients since: (a) replication of these results in an independent sample of patients is essential, and (b) identification of other genes in the overall pathogenesis of what is undoubtedly a polygenic predisposition will be needed.
EFFICACY AND TOXICITY OF DRUGS USED FOR OPPORTUNISTIC INFECTIONS
The use of drugs to treat opportunistic infections (and their use for prophylaxis) has declined since the advent of HAART. 109, 110 A large number of drugs are still used for opportunistic infections in HIV disease though, and it is beyond the scope of this review to cover all agents. Nevertheless, it is important to be aware that both efficacy and toxicity of these compounds is subject to inter-individual variability in pharmacokinetic and pharmacodynamic parameters. An example of a drug where genetic polymorphism is important for both efficacy and toxicity is isoniazid, which is used in the treatment of TB. Isoniazid undergoes N-acetylation by the polymorphically expressed phase II enzyme N-acetyltransferase type 2 (NAT-2), which is deficient in 50% of Caucasians. 111 The clearance of the drug is higher in fast acetylators than in slow acetylators, and this may lead to therapeutic failure. 111 By contrast, slow acetylators are more likely to develop adverse reactions such as peripheral neuropathy and SLE. 112 In HIV-negative patients, slow acetylator phenotype and genotype have been shown to be risk factors for hypersensitivity to sulphonamides. [113] [114] [115] In HIV patients, sulfamethoxazole (SMX) is the most commonly used sulphonamide, and is used for the treatment (in combination with trimethoprim) of Pneumocystis carinii pneumonia. 116 SMX hypersensitivity occurs at a frequency of between 30-50% in HIV-positive patients, in comparison to a frequency of 1-3% in HIVnegative patients. 93, 117 The mechanism of toxicity is thought to involve metabolism of SMX to toxic hydroxylamine and nitroso metabolites. 118, 119 It has thus been postulated that slow acetylators may form increased amounts of the toxic metabolites. Indeed, one study has shown that the slow acetylator phenotype is over-represented in SMX hypersensitive HIV-positive patients. 120 However, no relationship was shown between the slow acetylator genotype and SMX hypersensitivity. 121 The discordance between phenotype and genotype has been seen in HIV disease irrespective of whether patients were hypersensitive or not, 122 and may reflect either problems with the phenotyping assay or that an unidentified factor in the sera of HIV-positive patients inhibits N-acetyltransferase. In addition to the studies with NAT-2, we have also shown that polymorphisms in the glutathione transferase genes (GSTM1, GSTT1 and GSTP1) and CYP2C9 (which metabolises SMX to the The Pharmacogenomics Journal hydroxylamine metabolite) were not associated with susceptibility to SMX hypersensitivity. 121 Given the increasing laboratory evidence that SMX hypersensitivity is an immunemediated reaction, [123] [124] [125] whether polymorphisms in genes determining immune responsiveness are responsible for predisposition to SMX hypersensitivity is unknown.
CONCLUSIONS
Improvement in HAART through the application of pharmacogenomics is going to be a complex and difficult process. The genomics of both the virus and host will have to be considered for successful application of genotypic guided therapy (Figure 1 ). When one considers the virus, although a lot of mutations have been identified, the high capacity of the virus to mutate means that many more mutations or combinations of mutations will emerge, and much work will need to be performed to determine the phenotypic effect of the mutation(s). Even less is known about how the genetic constitution of the host affects response to antiretrovirals, although relevant studies are now beginning to be conducted. It is also important to note that when a genetic determinant of efficacy is identified in one ethnic population, it may not necessarily be relevant in another ethnic population because of the sometimes-marked ethnic variations in the frequency of polymorphisms. In order to unravel the complexity of HIV pharmacogenomics, a multi-pronged approach is going to be needed. This will need banking of DNA samples from on-going studies, and utilisation of archived samples, and subsequent determination of the relationship between genotypes of candidate genes and response to therapy. Where a particular relationship is identified in retrospective studies, carefully designed randomised prospective studies that incorporate not only measures of drug response, but also cost-effectiveness, will need to be performed. However, such prospective studies are unlikely to be possible when relatively rare adverse events are being studied. Taken together with the fact that many of these adverse reactions are unpredictable and are likely to be polygenic in predisposition, the recruitment of large numbers of patients through multi-centre collaborations is going to be essential. Paradoxically, this is probably going to be easier in HIV disease than in other conditions since the practice of multicentre international collaborations is well practised in the many antiretroviral drug studies that have been published to date. It is also important to remember that even when an association between host genotype and drug response may not institute changes in clinical practice in the short-term, it may have other benefits. For example, if a relationship between the MDR1 polymorphism and response to pro-tease inhibitors is demonstrated, this provides greater impetus and rationale to developing Pgp inhibitors that can be used to modulate drug entry to the sanctuary sites. The ultimate aim should be to develop an 'HIV response chip' that predicts the ideal drug combination to be used to maximise the response to the viral strain present, and prevent short-and long-term adverse effects to a group of drugs that have a relatively narrow therapeutic index. Clearly, this is a goal that is going to take a considerable length of time, but is nevertheless worth striving for.
